{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:19:42Z","timestamp":1785467982778,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although combination therapy is the gold standard for patients with pulmonary arterial hypertension (PAH), some of these patients are still being treated with monotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective analysis at four German PH centres to describe the prevalence and characteristics of patients receiving monotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 131 incident PAH patients, with a mean age of 64\u2009\u00b1\u200913.8\u00a0years and a varying prevalence of comorbidities, cardiovascular risk factors and targeted therapy. As in other studies, the extent of prescribed PAH therapy varied with age and coexisting diseases, and younger, so-called \u201ctypical\u201d PAH patients were more commonly treated early with combination therapy (48% at 4\u20138\u00a0months). In contrast, patients with multiple comorbidities or cardiovascular risk factors were more often treated with monotherapy (69% at 4\u20138\u00a0months). Survival at 12\u00a0months was not significantly associated with the number of PAH drugs used (single, dual, triple therapy) and was not different between \u201catypical\u201d and \u201ctypical\u201d PAH patients (89% vs. 85%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although \u201catypical\u201d PAH patients with comorbidities or a more advanced age are less aggressively treated with respect to combination therapy, the outcome of monotherapy in these patients appears to be comparable to that of dual or triple therapy in \u201ctypical\u201d PAH patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-021-01499-2","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T12:22:32Z","timestamp":1619007752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Monotherapy in patients with pulmonary arterial hypertension at four German PH centres"],"prefix":"10.1186","volume":"21","author":[{"given":"Beate","family":"Stubbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Seyfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Kleymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Halank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Al Ghorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Obst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Desole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Ewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"1499_CR1","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf AV, Beghetti M, Ghofrani A, Sanchez MAG, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) (vol 46, pg 903, 2015). Eur Respir J. 2015;46:1855\u20136.","journal-title":"Eur Respir J"},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1055\/s-0042-114526","volume":"141","author":"MM Hoeper","year":"2016","unstructured":"Hoeper MM, Apitz C, Grunig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kahler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S. Ghofrani HA [targeted therapy of pulmonary arterial hypertension: recommendations of the cologne consensus conference 2016]. Dtsch Med Wochenschr. 2016;141:S33\u201341.","journal-title":"Dtsch Med Wochenschr"},{"key":"1499_CR3","doi-asserted-by":"crossref","unstructured":"Galie N, Channick RN, Frantz RP, Grunig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal 2019; 53.","DOI":"10.1183\/13993003.01889-2018"},{"key":"1499_CR4","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/eurheartj\/ehq152","volume":"31","author":"N Galie","year":"2010","unstructured":"Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31:2080\u20136.","journal-title":"Eur Heart J"},{"key":"1499_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394\u2013403.","journal-title":"Eur Heart J"},{"key":"1499_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1465-9921-11-12","volume":"11","author":"CJ Ryerson","year":"2010","unstructured":"Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010;11:12.","journal-title":"Respir Res"},{"key":"1499_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1253\/circj.CJ-09-0971","volume":"74","author":"B He","year":"2010","unstructured":"He B, Zhang F, Li X, Tang C, Lin G, Du J, Jin H. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J. 2010;74:1458\u201364.","journal-title":"Circ J"},{"key":"1499_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","volume":"4","author":"AC Lajoie","year":"2016","unstructured":"Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291\u2013305.","journal-title":"Lancet Respir Med"},{"key":"1499_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D\u2019Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grunig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol. 2016;68:368\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1499_CR10","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.healun.2019.09.010","volume":"38","author":"VV McLaughlin","year":"2019","unstructured":"McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galie N, Barbera JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM, Group AS. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transpl. 2019;38:1286\u201395.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijcard.2018.08.082","volume":"272S","author":"MM Hoeper","year":"2018","unstructured":"Hoeper MM, Apitz C, Grunig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kahler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S, Ghofrani HA. Targeted therapy of pulmonary arterial hypertension: updated recommendations from the cologne consensus conference 2018. Int J Cardiol. 2018;272S:37\u201345.","journal-title":"Int J Cardiol"},{"key":"1499_CR12","doi-asserted-by":"crossref","unstructured":"Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50.","DOI":"10.1183\/13993003.00889-2017"},{"key":"1499_CR13","doi-asserted-by":"crossref","unstructured":"Hjalmarsson C, Radegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, Kjellstrom B, SveFph, Spahr. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J 2018; 51.","DOI":"10.1183\/13993003.02310-2017"},{"key":"1499_CR14","first-page":"50","volume":"2017","author":"MM Hoeper","year":"2015","unstructured":"Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, Olsson KM, Meyer K, Vizza CD, Vonk-Noordegraaf A, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Huscher D, Pittrow D, Rosenkranz S, Grunig E, Mortality in pulmonary arterial hypertension: prediction by the, . European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2015;2017:50.","journal-title":"Eur Respir J"},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chest.2015.11.005","volume":"150","author":"RC Bourge","year":"2016","unstructured":"Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH 3rd, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the delivery for PAH trial. Chest. 2016;150:27\u201334.","journal-title":"Chest"},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.healun.2019.05.002","volume":"38","author":"KM Olsson","year":"2019","unstructured":"Olsson KM, Richter MJ, Kamp JC, Gall H, Heine A, Ghofrani HA, Fuge J, Ewert R, Hoeper MM. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. J Heart Lung Transpl. 2019;38:748\u201356.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.healun.2018.11.015","volume":"38","author":"R Badagliacca","year":"2019","unstructured":"Badagliacca R, Papa S, Poscia R, Valli G, Pezzuto B, Manzi G, Torre R, Gianfrilli D, Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. J Heart Lung Transpl. 2019;38:306\u201314.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.chest.2018.03.050","volume":"154","author":"SD Bartolome","year":"2018","unstructured":"Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM. Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. Chest. 2018;154:532\u201340.","journal-title":"Chest"},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Galie","year":"2015","unstructured":"Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grunig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, Investigators A. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834\u201344.","journal-title":"N Engl J Med"},{"key":"1499_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, Investigators S. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318.","journal-title":"N Engl J Med"},{"key":"1499_CR21","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Investigators G. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522\u201333.","journal-title":"N Engl J Med"},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ijcard.2015.11.001","volume":"203","author":"MM Hoeper","year":"2016","unstructured":"Hoeper MM, Huscher D, Pittrow D. Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol. 2016;203:612\u20133.","journal-title":"Int J Cardiol"},{"key":"1499_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1378\/chest.09-1140","volume":"137","author":"DB Badesch","year":"2010","unstructured":"Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137:376\u201387.","journal-title":"Chest"},{"key":"1499_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","volume":"107","author":"S Rich","year":"1987","unstructured":"Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216\u201323.","journal-title":"Ann Intern Med"},{"key":"1499_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","volume":"173","author":"M Humbert","year":"2006","unstructured":"Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023\u201330.","journal-title":"Am J Respir Crit Care Med"},{"key":"1499_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1183\/09031936.00101211","volume":"40","author":"P Escribano-Subias","year":"2012","unstructured":"Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, Castillo-Palma MJ, Segovia J, Gomez-Sanchez MA, Barbera JA, Investigators R. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40:596\u2013603.","journal-title":"Eur Respir J"},{"key":"1499_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1183\/09031936.00078411","volume":"39","author":"J Hurdman","year":"2012","unstructured":"Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM, Capener D, Sephton P, Hamilton N, Armstrong IJ, Billings C, Lawrie A, Sabroe I, Akil M, O\u2019Toole L, Kiely DG. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J. 2012;39:945\u201355.","journal-title":"Eur Respir J"},{"key":"1499_CR28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ijcard.2012.10.026","volume":"168","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Grohe C, Lange TJ, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert R, Seyfarth HJ, Olsson KM, Opitz CF, Gaine SP, Vizza CD, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Pittrow D. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168:871\u201380.","journal-title":"Int J Cardiol"},{"key":"1499_CR29","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1164\/rccm.201801-0059LE","volume":"198","author":"GA Heresi","year":"2018","unstructured":"Heresi GA, Love TE, Tonelli AR, Highland KB, Dweik RA. Choice of initial oral therapy for pulmonary arterial hypertension: age and long-term survival. Am J Respir Crit Care Med. 2018;198:1090\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"1499_CR30","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","volume":"39","author":"D Kylhammar","year":"2018","unstructured":"Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, Wikstrom G, Radegran G. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39:4175\u201381.","journal-title":"Eur Heart J"},{"issue":"Astr Suppl","key":"1499_CR31","first-page":"2196","volume":"191","author":"VGN Mclaughlin","year":"2015","unstructured":"Mclaughlin VGN, Barbera JA, Frost A, Ghofrani HA, Hoeper M, Peacock AJ, Simmoneau G, Vachiery J-L, Blair C, Gillies HC, Harris J, Langley J, Rubin LJ. A comparison of characteristics and outcomes of patients with atypical and classical pulmonary arterial hypertension from the AMBITION trial [abstract]. Am J Resp Crit Care Med. 2015;191(Astr Suppl):2196.","journal-title":"Am J Resp Crit Care Med"},{"key":"1499_CR32","doi-asserted-by":"crossref","unstructured":"Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur Respir Rev 2019; 28.","DOI":"10.1183\/16000617.0050-2019"},{"key":"1499_CR33","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297\u2013317.","journal-title":"Eur Heart J"},{"key":"1499_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1378\/chest.11-1903","volume":"141","author":"AR Tonelli","year":"2012","unstructured":"Tonelli AR, Plana JC, Heresi GA, Dweik RA. Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension. Chest. 2012;141:1457\u201365.","journal-title":"Chest"},{"key":"1499_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.healun.2014.09.016","volume":"34","author":"RL Benza","year":"2015","unstructured":"Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, McGoon MD. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transpl. 2015;34:356\u201361.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MCP.0000000000000510","volume":"24","author":"J Weatherald","year":"2018","unstructured":"Weatherald J, Boucly A, Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr Opin Pulm Med. 2018;24:407\u201315.","journal-title":"Curr Opin Pulm Med"},{"key":"1499_CR37","doi-asserted-by":"publisher","first-page":"e35310","DOI":"10.1371\/journal.pone.0035310","volume":"7","author":"S Pabst","year":"2012","unstructured":"Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, Woitas R, Skowasch D. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS ONE. 2012;7:e35310.","journal-title":"PLoS ONE"},{"key":"1499_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1055\/a-1069-0691","volume":"74","author":"J Ortwein","year":"2020","unstructured":"Ortwein J, Feustel A, Reichenberger F. Prevalence of pulmonary hypertension in dialysis patients with end-stage renal disease. Pneumologie. 2020;74:210\u20136.","journal-title":"Pneumologie"},{"key":"1499_CR39","doi-asserted-by":"crossref","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.","DOI":"10.1183\/13993003.01913-2018"},{"key":"1499_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jchf.2019.09.004","volume":"7","author":"JA Regan","year":"2019","unstructured":"Regan JA, Kitzman DW, Leifer ES, Kraus WE, Fleg JL, Forman DE, Whellan DJ, Wojdyla D, Parikh K, O\u2019Connor CM, Mentz RJ. Impact of age on comorbidities and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2019;7:1056\u201365.","journal-title":"JACC Heart Fail"},{"key":"1499_CR41","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1164\/rccm.201209-1665OC","volume":"187","author":"LE Vanfleteren","year":"2013","unstructured":"Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, Rutten EP, Op\u2019t Roodt J, Wouters EF, Franssen FM. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:728\u201335.","journal-title":"Am J Respir Crit Care Med"},{"key":"1499_CR42","doi-asserted-by":"publisher","first-page":"K21","DOI":"10.1093\/eurheartj\/suz205","volume":"21","author":"IM Lang","year":"2019","unstructured":"Lang IM, Palazzini M. The burden of comorbidities in pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21:K21\u20138.","journal-title":"Eur Heart J Suppl"},{"key":"1499_CR43","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1093\/eurheartj\/ehz746.0032","volume":"40","author":"SCR Rosenkranz","year":"2019","unstructured":"Rosenkranz SCR, Chin K, Jenner B, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Mclaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson V, Lang IM. Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities. Eur Heart J. 2019;40:4973.","journal-title":"Eur Heart J"},{"key":"1499_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.healun.2019.12.012","volume":"39","author":"R Badagliacca","year":"2020","unstructured":"Badagliacca R, Rischard F, Papa S, Kubba S, Vanderpool R, Yuan JX, Garcia JGN, Airhart S, Poscia R, Pezzuto B, Manzi G, Miotti C, Luongo F, Scoccia G, Sciomer S, Torre R, Fedele F, Vizza CD. Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. J Heart Lung Transpl. 2020;39:310\u201320.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/2045-8932.109910","volume":"3","author":"PR Forfia","year":"2013","unstructured":"Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes. Pulm Circ. 2013;3:5\u201319.","journal-title":"Pulm Circ"},{"key":"1499_CR46","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","volume":"39","author":"MM Hoeper","year":"2020","unstructured":"Hoeper MM, Pausch C, Grunig E, Klose H, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Benjamin N, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Jureviciene E, Paleviciute E, Miliauskas S, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Wirtz H, Pfeuffer-Jovic E, Harbaum L, Scholtz W, Dumitrescu D, Bruch L, Coghlan G, Neurohr C, Tsangaris I, Gorenflo M, Scelsi L, Vonk-Noordegraaf A, Ulrich S, Held M. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transpl. 2020;39:1435\u201344.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR47","doi-asserted-by":"crossref","unstructured":"Samson R, Jaiswal A, Ennezat PV, Cassidy M, Le Jemtel TH. Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc 2016; 5.","DOI":"10.1161\/JAHA.115.002477"},{"key":"1499_CR48","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12325-014-0094-z","volume":"31","author":"M Small","year":"2014","unstructured":"Small M, Piercy J, Pike J, Cerulli A. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy. Adv Ther. 2014;31:168\u201379.","journal-title":"Adv Ther"},{"key":"1499_CR49","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.healun.2013.08.010","volume":"32","author":"HW Farber","year":"2013","unstructured":"Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transpl. 2013;32:1114\u201322.","journal-title":"J Heart Lung Transpl"},{"key":"1499_CR50","first-page":"291","volume":"24","author":"CD Burger","year":"2018","unstructured":"Burger CD, Pruett JA, Lickert CA, Berger A, Murphy B, Drake W 3rd. Prostacyclin use among patients with pulmonary arterial hypertension in the united states: a retrospective analysis of a large health care claims database. J Manag Care Spec Pharm. 2018;24:291\u2013302.","journal-title":"J Manag Care Spec Pharm"},{"key":"1499_CR51","doi-asserted-by":"publisher","first-page":"K29","DOI":"10.1093\/eurheartj\/suz206","volume":"21","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Howard L. Management of pulmonary arterial hypertension in patients aged over 65 years. Eur Heart J Suppl. 2019;21:K29\u201336.","journal-title":"Eur Heart J Suppl"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01499-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T13:09:28Z","timestamp":1619010568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01499-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01499-2","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent was waived by an Institutional Review Board (IRB). The study was approved by the ethics committee of the University of Greifswald (Reg. No. BB 167\/18, with an amendment to extend the observation period). No administrative permissions and\/or licenses were acquired by our team to access the clinical\/personal patient data used in our research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}